# A Study of Fabrazyme in Pediatric Patients With Fabry Disease

> **NCT00074958** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 16 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** Fabrazyme (agalsidase beta)

## Key facts

- **NCT ID:** NCT00074958
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2005-05
- **Final completion:** 2005-07
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2015-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074958, "A Study of Fabrazyme in Pediatric Patients With Fabry Disease". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00074958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*